{
    "xml": "<topic id=\"PHP1385\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/ivabradine\" basename=\"ivabradine\" title=\"IVABRADINE\">\n<title>IVABRADINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1050\" namespace=\"/interactions/list-of-drug-interactions/ivabradine\">Ivabradine</xref>\n</p>\n<data name=\"vtmid\">421692002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_801070824\" title=\"Selective sinus node If inhibitors\">Selective sinus node If inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP51876\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/ivabradine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of angina in patients in normal sinus rhythm</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg twice daily for 3&#8211;4 weeks, then increased if necessary to 7.5&#8239;mg twice daily; reduced if not tolerated to 2.5&#8211;5&#8239;mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 2.5&#8239;mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mild to severe chronic heart failure</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg twice daily for 2 weeks, then increased if necessary to 7.5&#8239;mg twice daily; reduced if not tolerated to 2.5&#8239;mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51924\" outputclass=\"contraindications\" rev=\"1.24\" parent=\"/drugs/ivabradine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Acute myocardial infarction</ph>; <ph outputclass=\"contraindication\">cardiogenic shock</ph>; <ph outputclass=\"contraindication\">congenital QT syndrome</ph>; <ph outputclass=\"contraindication\">do not initiate for angina if heart rate below 70 beats per minute</ph>; <ph outputclass=\"contraindication\">do not initiate for chronic heart failure if heart rate below 75 beats per minute</ph>; <ph outputclass=\"contraindication\">immediately after cerebrovascular accident</ph>; <ph outputclass=\"contraindication\">patients dependent on pacemaker</ph>; <ph outputclass=\"contraindication\">second- and third-degree heart block</ph>; <ph outputclass=\"contraindication\">severe hypotension</ph>; <ph outputclass=\"contraindication\">sick-sinus syndrome</ph>; <ph outputclass=\"contraindication\">sino-atrial block</ph>; <ph outputclass=\"contraindication\">unstable angina</ph>; <ph outputclass=\"contraindication\">unstable or acute heart failure</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51940\" outputclass=\"cautions\" rev=\"1.27\" parent=\"/drugs/ivabradine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Atrial fibrillation or other arrhythmias (treatment ineffective)</ph>; <ph outputclass=\"caution\">elderly</ph>; <ph outputclass=\"caution\">in angina, consider stopping if there is no or limited symptom improvement after 3 months</ph>; <ph outputclass=\"caution\">intraventricular conduction defects</ph>; <ph outputclass=\"caution\">mild to moderate hypotension (avoid if severe)</ph>; <ph outputclass=\"caution\">retinitis pigmentosa</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51862\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/ivabradine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ivabradine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51818\" outputclass=\"sideEffects\" rev=\"1.19\" parent=\"/drugs/ivabradine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Atrial fibrillation</ph>; <ph outputclass=\"sideEffect\">blurred vision</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">first-degree heart block</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">phosphenes</ph>; <ph outputclass=\"sideEffect\">ventricular extrasystoles</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angioedema</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">eosinophilia</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">muscle cramps</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">palpitations</ph>; <ph outputclass=\"sideEffect\">raised plasma-creatinine concentration</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">supraventricular extrasystoles</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Second and third-degree heart block</ph>; <ph outputclass=\"sideEffect\">sick sinus syndrome</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51856\" outputclass=\"pregnancy\" parent=\"/drugs/ivabradine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;<i>toxicity</i> in animal studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51947\" outputclass=\"breastFeeding\" parent=\"/drugs/ivabradine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk in <i>animal </i>studies&#8212;manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51896\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ivabradine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51842\" outputclass=\"renalImpairment\" parent=\"/drugs/ivabradine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use with caution if eGFR less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51725\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ivabradine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"patientMonitoringProgrammes\">\n<sectiondiv>\n<p>Monitor regularly for atrial fibrillation (consider benefits and risks of continued treatment if atrial fibrillation occurs).</p>\n<p>Monitor for bradycardia, especially after any dose increase, and discontinue if resting heart rate persistently below 50 beats per minute or continued symptoms of bradycardia despite dose reduction.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51541\" outputclass=\"nationalFunding\" rev=\"1.17\" parent=\"/drugs/ivabradine\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA267</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ivabradine for the treatment of chronic heart failure (November 2012)</p>\r\n<p>Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), an ACE inhibitor, and an aldosterone antagonist, is an option for treating mild to severe stable chronic heart failure in patients who:</p>\n<ol>\r\n<li>have a left ventricular ejection fraction of &#8804; 35%, <i>and</i>\r\n</li>\r\n<li>are in sinus rhythm with a heart rate of &#8805;75 beats per minute</li>\n</ol>\r\n<p>Ivabradine should be initiated only by a heart failure specialist after 4 weeks of stable optimal standard therapy; monitoring and dose titration should be carried out by a heart failure specialist, or a GP with special interest in heart failure, or by a heart failure specialist nurse.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA267\">www.nice.org.uk/TA267</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (September 2012) that ivabradine (<i>Procoralan</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland in accordance with its licensed indication for heart failure only if resting heart rate remains &#8805;75 beats per minute despite optimal standard therapy.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1385-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ivabradine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74799\" title=\"Tablet\" namespace=\"/drugs/ivabradine/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78150\" namespace=\"/treatment-summaries/stable-angina\" title=\"Stable angina\" count=\"4\" rel=\"backlink\">Stable angina</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1050\" namespace=\"/interactions/list-of-drug-interactions/ivabradine\" title=\"Ivabradine\" count=\"1\" rel=\"link\">Ivabradine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74799\" namespace=\"/drugs/ivabradine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1385",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/ivabradine",
    "basename": "ivabradine",
    "title": "IVABRADINE",
    "interactants": [
        {
            "id": "bnf_int_1050",
            "label": "Ivabradine"
        }
    ],
    "vtmid": "421692002",
    "drugClassification": [
        "Selective sinus node If inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of angina in patients in normal sinus rhythm",
                        "html": "Treatment of angina in patients in normal sinus rhythm"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg twice daily for 3&#8211;4 weeks, then increased if necessary to 7.5 mg twice daily; reduced if not tolerated to 2.5&#8211;5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.",
                        "html": "<p>Initially 5&#8239;mg twice daily for 3&#8211;4 weeks, then increased if necessary to 7.5&#8239;mg twice daily; reduced if not tolerated to 2.5&#8211;5&#8239;mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.</p>"
                    },
                    {
                        "textContent": "Initially 2.5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.",
                        "html": "<p>Initially 2.5&#8239;mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mild to severe chronic heart failure",
                        "html": "Mild to severe chronic heart failure"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg twice daily for 2 weeks, then increased if necessary to 7.5 mg twice daily; reduced if not tolerated to 2.5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.",
                        "html": "<p>Initially 5&#8239;mg twice daily for 2 weeks, then increased if necessary to 7.5&#8239;mg twice daily; reduced if not tolerated to 2.5&#8239;mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute myocardial infarction",
                "html": "Acute myocardial infarction"
            },
            {
                "type": "contraindications",
                "textContent": "cardiogenic shock",
                "html": "cardiogenic shock"
            },
            {
                "type": "contraindications",
                "textContent": "congenital QT syndrome",
                "html": "congenital QT syndrome"
            },
            {
                "type": "contraindications",
                "textContent": "do not initiate for angina if heart rate below 70 beats per minute",
                "html": "do not initiate for angina if heart rate below 70 beats per minute"
            },
            {
                "type": "contraindications",
                "textContent": "do not initiate for chronic heart failure if heart rate below 75 beats per minute",
                "html": "do not initiate for chronic heart failure if heart rate below 75 beats per minute"
            },
            {
                "type": "contraindications",
                "textContent": "immediately after cerebrovascular accident",
                "html": "immediately after cerebrovascular accident"
            },
            {
                "type": "contraindications",
                "textContent": "patients dependent on pacemaker",
                "html": "patients dependent on pacemaker"
            },
            {
                "type": "contraindications",
                "textContent": "second- and third-degree heart block",
                "html": "second- and third-degree heart block"
            },
            {
                "type": "contraindications",
                "textContent": "severe hypotension",
                "html": "severe hypotension"
            },
            {
                "type": "contraindications",
                "textContent": "sick-sinus syndrome",
                "html": "sick-sinus syndrome"
            },
            {
                "type": "contraindications",
                "textContent": "sino-atrial block",
                "html": "sino-atrial block"
            },
            {
                "type": "contraindications",
                "textContent": "unstable angina",
                "html": "unstable angina"
            },
            {
                "type": "contraindications",
                "textContent": "unstable or acute heart failure",
                "html": "unstable or acute heart failure"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Atrial fibrillation or other arrhythmias (treatment ineffective)",
                "html": "Atrial fibrillation or other arrhythmias (treatment ineffective)"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            },
            {
                "type": "cautions",
                "textContent": "in angina, consider stopping if there is no or limited symptom improvement after 3 months",
                "html": "in angina, consider stopping if there is no or limited symptom improvement after 3 months"
            },
            {
                "type": "cautions",
                "textContent": "intraventricular conduction defects",
                "html": "intraventricular conduction defects"
            },
            {
                "type": "cautions",
                "textContent": "mild to moderate hypotension (avoid if severe)",
                "html": "mild to moderate hypotension (avoid if severe)"
            },
            {
                "type": "cautions",
                "textContent": "retinitis pigmentosa",
                "html": "retinitis pigmentosa"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ivabradine).",
                "html": "<p>Appendix 1 (ivabradine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Atrial fibrillation",
                        "html": "Atrial fibrillation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "blurred vision",
                        "html": "blurred vision",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "first-degree heart block",
                        "html": "first-degree heart block",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "phosphenes",
                        "html": "phosphenes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "ventricular extrasystoles",
                        "html": "ventricular extrasystoles",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Angioedema",
                        "html": "Angioedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "eosinophilia",
                        "html": "eosinophilia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "muscle cramps",
                        "html": "muscle cramps",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "palpitations",
                        "html": "palpitations",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "raised plasma-creatinine concentration",
                        "html": "raised plasma-creatinine concentration",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "supraventricular extrasystoles",
                        "html": "supraventricular extrasystoles",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Second and third-degree heart block",
                        "html": "Second and third-degree heart block",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "sick sinus syndrome",
                        "html": "sick sinus syndrome",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;<i>toxicity</i> in animal studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk in animal studies&#8212;manufacturer advises avoid.",
                "html": "<p>Present in milk in <i>animal </i>studies&#8212;manufacturer advises avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in moderate impairment.\n\nAvoid in severe impairment.",
                "html": "<p>Manufacturer advises caution in moderate impairment.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use with caution if eGFR less than 15 mL/minute/1.73 m2&#8212;no information available.",
                "html": "<p>Manufacturer advises use with caution if eGFR less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientMonitoringProgrammes": [
            {
                "type": "patientMonitoringProgrammes",
                "textContent": "Monitor regularly for atrial fibrillation (consider benefits and risks of continued treatment if atrial fibrillation occurs).\n\nMonitor for bradycardia, especially after any dose increase, and discontinue if resting heart rate persistently below 50 beats per minute or continued symptoms of bradycardia despite dose reduction.",
                "html": "<p>Monitor regularly for atrial fibrillation (consider benefits and risks of continued treatment if atrial fibrillation occurs).</p><p>Monitor for bradycardia, especially after any dose increase, and discontinue if resting heart rate persistently below 50 beats per minute or continued symptoms of bradycardia despite dose reduction.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA267",
                        "label": "www.nice.org.uk/TA267"
                    }
                ],
                "fundingIdentifier": "NICE TA267",
                "textContent": "Ivabradine for the treatment of chronic heart failure (November 2012) Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), an ACE inhibitor, and an aldosterone antagonist, is an option for treating mild to severe stable chronic heart failure in patients who: have a left ventricular ejection fraction of &#8804; 35%, and are in sinus rhythm with a heart rate of &#8805;75 beats per minute Ivabradine should be initiated only by a heart failure specialist after 4 weeks of stable optimal standard therapy; monitoring and dose titration should be carried out by a heart failure specialist, or a GP with special interest in heart failure, or by a heart failure specialist nurse.\n\nwww.nice.org.uk/TA267",
                "html": "<p outputclass=\"title\">Ivabradine for the treatment of chronic heart failure (November 2012)</p> <p>Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), an ACE inhibitor, and an aldosterone antagonist, is an option for treating mild to severe stable chronic heart failure in patients who:</p> <ol> <li>have a left ventricular ejection fraction of &#8804; 35%, <i>and</i> </li> <li>are in sinus rhythm with a heart rate of &#8805;75 beats per minute</li> </ol> <p>Ivabradine should be initiated only by a heart failure specialist after 4 weeks of stable optimal standard therapy; monitoring and dose titration should be carried out by a heart failure specialist, or a GP with special interest in heart failure, or by a heart failure specialist nurse.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA267\">www.nice.org.uk/TA267</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74799",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78150",
                "label": "Stable angina",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1050",
                "label": "Ivabradine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74799",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}